Rex Bionics

Norway
Sandnes, Rogaland, Norway, 0751

Company profile

Rex Bionics company profile

Rex Bionics Plc is engaged in the research and development, manufacture, and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.

Business identity

Contact email
[email protected]
Phone number
+64 9 440 9741
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2007-01-01, Year

Headquarters

Postal code
0751
Country code
NO
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
8
Total equity funding
$26.5M
Last funding
Grant / $13,487 / 2024-07-01
Last equity funding
Post IPO Equity / $995,596
Investors
4
Lead investors
3
Founders
2
Articles
19
Exited on
2014-05-16

Founders and investors

Founders

Richard LittleRobert Irving

Lead investors

Callaghan InnovationMRCF Biomedical Translation FundSante Ventures

Investors

BioScience Managers LimitedCallaghan InnovationMRCF Biomedical Translation FundSante Ventures